@article{b6318f6d43444b7499aa24a225e3eea9,
title = "Adjunctive Therapies in Parkinson Disease - Have We Made Meaningful Progress?",
author = "Tanya Simuni and Okun, {Michael S.}",
note = "Funding Information: reported receiving grants from Amneal Pharmaceuticals, Biogen, the Michael J. Fox Foundation, NeuroDerm, the National Institute of Neurological Disorders and Stroke, the Parkinson's Foundation, Prevail Therapeutics, Roche, Sanofi, Sun Pharmaceutical Industries, and UCB and serving as a consultant or advisor for Acadia Pharmaceuticals, BlueRock Therapeutics, Caraway Therapeutics, the Critical Path for Parkinson's Consortium, Denali Therapeutics, GE Healthcare,",
year = "2022",
month = feb,
doi = "10.1001/jamaneurol.2021.4140",
language = "English (US)",
volume = "79",
pages = "119--120",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "2",
}